Your search history is turned on.
Date: November 25, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Microsoft Word - 119759012_v(4)_Project Fran - Notice of Change in Corporate Structure.DOCX 328972.00001/119759012.4 EMERALD HEALTH THERAPEUTICS, INC. NOTICE OF CHANGE IN CORPORATE STRUCTURE (Pursuant to Section 4.9 of National Instrument 51-102 Continuous Disclosure Obligations) 1. Name of the parties to the transaction: Emerald Health Therapeut...
Date: November 14, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Microsoft Word - 119768785_v(2)_Project Fran - Material Change Report.DOC FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Emerald Health Therapeutics, Inc. (Emerald or the Company) 101 4226 Commerce Circle Victoria, British Columbia V8Z 6N6, Canada 2. Date of Material Change November 10, 2022. 3. News Release ...
Date: November 11, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Microsoft Word - 119816203_v(2)_Project Fran - Early Warning Report.DOCX FORM 62-103F1 REQUIRED DISCLOSURE UNDER THE EARLY WARNING REQUIREMENTS Item 1 Security and Reporting Issuer 1.1 State the designation of securities to which this report relates and the name and address of the head office of the issuer of the securities. This report relates to the ...
Date: November 10, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Microsoft Word - 221110 NR EHT closing Final (002).docx Emerald Health Therapeutics and Skye Bioscience Close Plan of Arrangement VANCOUVER, BC, November 10, 2022 Emerald Health Therapeutics, Inc. ("Emerald" or the "Company") (CSE: EMH; OTCQB: EMHTF) announced today that its Plan of Arrangement with Skye Bioscience, Inc. (Skye) has...
Date: November 7, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Emerald Health Therapeutics and Skye Bioscience Announce Intended Closing Date of Plan of Arrangement Skye will continue to pursue Canadian Securities Exchange listing following closing of transaction Vancouver, British Columbia--(Newsfile Corp. - November 7, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") and Skye Bioscience, Inc. (OTCQB: SKYE) ("S...
Date: October 18, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Emerald Health Therapeutics Announces Bridge Loan to Skye Bioscience and Provides Update on Merger Vancouver, British Columbia--(Newsfile Corp. - October 18, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") reports that it has provided a short-term bridge loan of US$700,000 to Skye Bioscience, Inc. ("Skye") in order to provide Skye with additional wo...
Date: August 31, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Emerald Health Therapeutics, Inc. Reports 2022 Q2 Results Vancouver, British Columbia--(Newsfile Corp. - August 31, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") has reported financial results for the quarter ended June 30, 2021. Selected Financial Information The financial information presented for the years below was derived from financial...
Date: August 30, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
EMERALD HEALTH THERAPEUTICS, INC. Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Moe Jiwan, Chief Operating Office, in the capacity of chief executive officer and chief financial officer, of Emerald Health Therapeutics, Inc., certify the following: 1. Review: I have reviewed the interim financial report and ...
Skye Bioscience, Inc. (Proxy DEF) 1 Emerald Health Therapeutics Inc. (CSE : EMH) Management Discussion & Analysis For the three and six months ended June 30, 2022 and 2021 2 TABLE OF CONTENTS Overview 3 Disclosure of Outstanding Share Data 7 ...